Link Cell Therapies is a biotechnology company focused on developing precise CAR T cell therapies for cancer. Founded by Stanford researchers and backed by Samsara BioCapital, the company aims to safely deploy CAR T beyond current indications using a true AND-gate logic to require co-expression of cancer targets for tumor-specific cytotoxicity. Their programs target solid tumors and select hematologic cancers, with multiple platforms under development to expand the potential of CAR T therapies. Based in the San Francisco Bay Area, the company emphasizes translational immunotherapy research and